Title:
MEDICAL AGENT FOR TREATING OR SUPPRESSING PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS
Document Type and Number:
WIPO Patent Application WO/2023/149539
Kind Code:
A1
Abstract:
Disclosed is a medical agent that is for treating or suppressing progression of at least one symptom selected from the group consisting of symptoms of amyotrophic lateral sclerosis and symptoms caused by amyotrophic lateral sclerosis in a subject. The medical agent contains 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, or a hydrate or a solvate thereof. The blood uric acid level in the subject before administration of the medical agent is at least 4.2 mg/dL.
More Like This:
Inventors:
TAKAHASHI FUMIHIRO (JP)
USHIROGAWA YOSHITERU (JP)
USHIROGAWA YOSHITERU (JP)
Application Number:
PCT/JP2023/003542
Publication Date:
August 10, 2023
Filing Date:
February 03, 2023
Export Citation:
Assignee:
MITSUBISHI TANABE PHARMA CORP (JP)
International Classes:
A61K31/4152; A61P11/00; A61P21/00; A61P25/02; A61P43/00
Domestic Patent References:
| WO2020091036A1 | 2020-05-07 |
Other References:
ATASSI NAZEM, BERRY JAMES, SHUI AMY, ZACH NETA, SHERMAN ALEXANDER, SINANI ERVIN, WALKER JASON, KATSOVSKIY IGOR, SCHOENFELD DAVID, : "The PRO-ACT database: design, initial analyses, and predictive features", NEUROLOGY, vol. 83, no. 19, 1 January 2014 (2014-01-01), pages 1719 - 1725, XP093082304, DOI: 10.1212/WNL.0000000000000951 OLITCiteNPL
YORIHIRO YAMAMOTO, @BULLET LOO, VE +, LOOH →: "Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite", REVIEW J. CLIN. BIOCHEM. NUTR. | JANUARY, 1 January 2017 (2017-01-01), pages 49 - 54, XP055691312, Retrieved from the Internet [retrieved on 20200504], DOI: 10.3164/jcbn.16-63
HAN HEE JO, SHIN HA YOUNG, CHOI YOUNG-CHUL, KIM SEUNG MIN: "Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone", REDOX REPORT., CHURCHILL LIVINGSTONE, EDINBURGH., GB, vol. 27, no. 1, 31 December 2022 (2022-12-31), GB , pages 79 - 84, XP093082305, ISSN: 1351-0002, DOI: 10.1080/13510002.2022.2051964
TAKAHASHI FUMIHIRO, KANO OSAMU, NAGANO YOSHITO, YONEOKA TAKATOMO, NELSON SALLY, USHIROGAWA YOSHITERU: "Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19", MUSCLE AND NERVEMUSCLE, JOHN WILEY & SONS, INC., HOBOKEN, USA, vol. 66, no. 5, 1 November 2022 (2022-11-01), Hoboken, USA, pages 583 - 592, XP093082306, ISSN: 0148-639X, DOI: 10.1002/mus.27699
TAKAHASHI FUMIHIRO, KANO OSAMU, NAGANO YOSHITO, YONEOKA TAKATOMO, NELSON SALLY, USHIROGAWA YOSHITERU: " Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19", MUSCLE AND NERVEMUSCLE, JOHN WILEY & SONS, INC., HOBOKEN, USA, vol. 66, no. 5, 1 November 2022 (2022-11-01), Hoboken, USA, pages 593 - 602, XP093082308, ISSN: 0148-639X, DOI: 10.1002/mus.27700
YORIHIRO YAMAMOTO, @BULLET LOO, VE +, LOOH →: "Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite", REVIEW J. CLIN. BIOCHEM. NUTR. | JANUARY, 1 January 2017 (2017-01-01), pages 49 - 54, XP055691312, Retrieved from the Internet
HAN HEE JO, SHIN HA YOUNG, CHOI YOUNG-CHUL, KIM SEUNG MIN: "Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone", REDOX REPORT., CHURCHILL LIVINGSTONE, EDINBURGH., GB, vol. 27, no. 1, 31 December 2022 (2022-12-31), GB , pages 79 - 84, XP093082305, ISSN: 1351-0002, DOI: 10.1080/13510002.2022.2051964
TAKAHASHI FUMIHIRO, KANO OSAMU, NAGANO YOSHITO, YONEOKA TAKATOMO, NELSON SALLY, USHIROGAWA YOSHITERU: "Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19", MUSCLE AND NERVEMUSCLE, JOHN WILEY & SONS, INC., HOBOKEN, USA, vol. 66, no. 5, 1 November 2022 (2022-11-01), Hoboken, USA, pages 583 - 592, XP093082306, ISSN: 0148-639X, DOI: 10.1002/mus.27699
TAKAHASHI FUMIHIRO, KANO OSAMU, NAGANO YOSHITO, YONEOKA TAKATOMO, NELSON SALLY, USHIROGAWA YOSHITERU: " Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19", MUSCLE AND NERVEMUSCLE, JOHN WILEY & SONS, INC., HOBOKEN, USA, vol. 66, no. 5, 1 November 2022 (2022-11-01), Hoboken, USA, pages 593 - 602, XP093082308, ISSN: 0148-639X, DOI: 10.1002/mus.27700
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF: